Paolo Ghia, MD, PhD, on CLL: New Data on Treatment With Ibrutinib Plus Venetoclax

2021 ASH Annual Meeting & Exposition


Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, discusses disease-free survival results from the measurable residual disease cohort of the phase II CAPTIVATE trial. This multicenter trial focuses on first-line ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia (Abstract 68).

Related Videos

Multiple Myeloma

Anil Aktas-Samur, PhD, on Identifying Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD, of Dana-Farber Cancer Institute, discusses study findings on the genomic characterization of non-progressor smoldering multiple myeloma, results that may provide a molecular definition of the disease as well as its risk-driving features. Combining this low-risk model with current high-risk models may possibly improve clinical trials for patients with this early precursor to myeloma (Abstract 545).



Daniel A. Ermann, MD, on DLBCL: Outcomes With Consolidative Radiation Therapy

Daniel A. Ermann, MD, of the Huntsman Cancer Institute, University of Utah, discusses results from the largest retrospective study on outcomes utilizing radiotherapy in early-stage diffuse large B-cell lymphoma. Adding radiation to front-line multiagent chemotherapy was associated with a survival benefit for all patients with early-stage disease. An overall survival benefit was seen with the addition of radiation to front-line multiagent chemotherapy for patients with nodal involvement and those with specific extranodal involvement in the testes, thyroid, skin and soft tissue, and head and neck (Abstract 49).

Multiple Myeloma

Tarek H. Mouhieddine, MD, on Relapsed/Refractory Multiple Myeloma and Bispecific Antibodies

Tarek H. Mouhieddine, MD, of The Mount Sinai Hospital and The Icahn School of Medicine at Mount Sinai, discusses data that suggest patients with heavily pretreated, predominantly triple-class refractory multiple myeloma who relapse after treatment with bispecific antibodies may still have good outcomes when sequentially treating with other immunologic treatments (Abstract 821).


Multiple Myeloma

Nikhil C. Munshi, MD, PhD, on COVID-19 Vaccine Effectiveness in Patients With Multiple Myeloma

Nikhil C. Munshi, MD, PhD, of Dana-Farber Cancer Institute, discusses the findings from a large nationwide Veterans Affairs study, which showed that, for patients with multiple myeloma, the effectiveness of the COVID-19 vaccine is reduced, likely due to patients’ immunosuppression. Dr. Munshi describes what next steps should be taken (Abstract 400).

Hematologic Malignancies
Supportive Care

Leslie S. Kean, MD, PhD, on Bone Marrow Transplantation: Using Abatacept to Prevent Graft-vs-Host Disease

Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, discusses findings from her analysis of the International Blood and Marrow Transplant Research Database, which led to the recent FDA approval of abatacept for the prevention of acute graft-vs-host disease (GVHD) in adult and pediatric patients. The data suggest improved overall survival with the immunosuppressant abatacept in combination with a calcineurin inhibitor and methotrexate following 7/8 HLA–matched unrelated allogeneic hematopoietic stem cell transplantation (Abstract 3912).